What does this research mean for the field?

Olanzapine treatment increases triglycerides, total cholesterol, and LDL-C while reducing HDL-C, particularly at higher doses and during early treatment. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To assess the time- and dose-dependent effects of olanzapine treatment on circulating lipid profiles in human populations.

January 10, 2026BMC Cardiovascular DisordersOpen Access

The effect of olanzapine on lipid profiles in humans: a time and dose response meta-analysis of randomized controlled trials

Q: What are the key findings of this study?

Olanzapine treatment increased triglycerides, total cholesterol, and LDL-C while reducing HDL-C, particularly at higher doses and early treatment.

View Full Paper

Ask AI

Bookmark

Key result

Olanzapine raises triglycerides, total cholesterol, and LDL-C while lowering HDL-C, particularly at higher doses.

Why the study?

Does olanzapine alter lipid profiles (TG, TC, HDL-C, LDL-C) in humans?

Population

Humans receiving olanzapine treatment

Comparison

Olanzapine at varying doses and durations vs control

Design

Time and dose response meta-analysis of randomized controlled trials

Authors

FZFang ZhouZhejiang Chinese Medical University PJParmida JamilianKeele University MSMohammad SafargarTabriz University of Medical Sciences

Discussion

Member takes

Implication

Requires lipid monitoring with olanzapine; confirms and extends RCT evidence of dose- and time-dependent dyslipidemia.

Key Points

To assess the time- and dose-dependent effects of olanzapine treatment on circulating lipid profiles in human populations.
Meta-analysis of 14 articles reporting 17 distinct randomized controlled trials across diverse global regions.
Included studies evaluated olanzapine doses ranging from 4.83 mg/day to 17.5 mg/day over durations spanning 3 days to 36 weeks in participants aged 8.5 to approximately 55 years.
Olanzapine significantly raised triglycerides across 15 study arms (N=1,664; WMD: 24.96 mg/dL, 95% CI: 13.74 to 36.19, P=0.000), with stronger increases at doses ≥ 10 mg/day (WMD: 35.55 mg/dL, 95% CI: 23.54 to 47.57, P≤0.001) and durations < 12 weeks (WMD: 33.85 mg/dL, 95% CI: 19.57 to 48.13, P=0.000).
Total cholesterol significantly increased across 16 study arms (N=2,124; WMD: 6.57 mg/dL, 95% CI: 2.14 to 11.01, P=0.004), whereas overall changes in HDL-C were not statistically significant across 13 study arms (N=1,660; WMD: -1.33 mg/dL, 95% CI: -3.28 to 0.60, P=0.178).
Participants with baseline BMI < 25 kg/m² showed greater elevations in triglycerides (WMD: 27.32 mg/dL, 95% CI: 16.47 to 38.16, P≤0.001) and total cholesterol (WMD: 7.63 mg/dL, 95% CI: 0.61 to 14.65, P=0.027), along with significant HDL-C reductions (WMD: -3.59 mg/dL, 95% CI: -5.21 to -1.96, P=0.000).

Structured PICO

Does olanzapine alter lipid profiles (TG, TC, HDL-C, LDL-C) in humans?

Population

17 RCTs pooling 2,124 participants (ranging from 14 to 308 per trial), including healthy volunteers, pediatric cancer patients, and individuals with psychiatric disorders (schizophrenia, bipolar I disorder, borderline personality disorder). Mean age ranged from 8.5 to 55 years, baseline BMI 18.5-25.4 kg/m2. Multinational (USA, Canada, China, Iran, Japan, India).

Intervention

Olanzapine at daily doses ranging from 4.83 mg/day to 17.5 mg/day, administered for durations ranging from 3 days to 36 weeks.

Comparator

Placebo

Outcome

Changes in lipid profiles (triglycerides [TG], total cholesterol [TC], high-density lipoprotein cholesterol [HDL-C], and low-density lipoprotein cholesterol [LDL-C]) before and after olanzapine treatment.surrogate

Olanzapine treatment causes significant dose- and time-dependent worsening of lipid profiles (increased TG, TC, LDL-C), highlighting the need for proactive lipid monitoring and cardiovascular risk assessment.

Limitations

Short follow-up duration in many trials restricts conclusions regarding long-term lipid trajectories and cardiovascular risk
Residual confounding remains possible despite subgroup and dose-response analyses
Important modifiers of lipid metabolism (dietary intake, physical activity, smoking status, baseline insulin resistance, use of lipid-lowering or antidiabetic medications) were not consistently reported or controlled for
Age-stratified analyses were not feasible due to limited data in certain subgroups, particularly pediatric populations
Many trials had relatively small sample sizes

Cite This Study

Zhou et al. (2026) studied this question. Olanzapine treatment increased triglycerides, total cholesterol, and LDL-C while reducing HDL-C, particularly at higher doses and early treatment.

synapsesocial.com/papers/696321d091e05aa366cb814e https://doi.org/10.1186/s12872-025-05476-z

View Full Paper

Ask AI

Bookmark

The effect of olanzapine on lipid profiles in humans: a time and dose response meta-analysis of randomized controlled trials

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

The effect of olanzapine on lipid profiles in humans: a time and dose response meta-analysis of randomized controlled trials

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider